Table 3. Trastuzumab treatment modifications by the 2430 patients with complete trastuzumab treatment information and who received trastuzumab.

	12-months patients	6-months patients	P-value
Number of patients	1214	1216
Treatment data in the 1st 6-month period	1214	1216
Treatment data in the 2nd 6-month period	1129	51a
No. of patients reporting delays	717 (59%)	496 (41%)	<0.0001
In 1st 6-month period	520/1214 (43%)	487/1216 (40%)
In 2nd 6-month period	424/1129 (38%)	20/51a (39%)
No. of patients reporting delays due to cardiotoxicity	72 (6%)	45 (4%)	0.01
In 1st 6-month period	40/1214 (3%)	43/1216 (4%)
In 2nd 6-month period	33/1129 (3%)	2/51a (4%)

^aDoses administered to patients who continued trastuzumab treatment beyond their randomised 6 months (9 doses).